Dissecting the proteome of lipoproteins: New biomarkers for cardiovascular diseases?  by von Zychlinski, Anne & Kleffmann, Torsten
Translational Proteomics 7 (2015) 30–39Dissecting the proteome of lipoproteins: New biomarkers for
cardiovascular diseases?
Anne von Zychlinski a, Torsten Kleffmann a,b,*
aDepartment of Biochemistry, University of Otago, Dunedin, New Zealand
bCentre for Protein Research, University of Otago, Dunedin, New Zealand
A R T I C L E I N F O
Article history:
Available online 5 January 2015
Keywords:
Lipoprotein proteomics
Absolute quantiﬁcation
Lipoprotein(a)
DIA-MS
Targeted proteomics
A B S T R A C T
Proteomics has proven to be a powerful tool for the characterization of lipoproteins and has provided
important insights into the biochemistry and pathophysiology of various lipoprotein classes. It has
signiﬁcantly contributed to the way we now see lipoproteins as complex particles not only involved in
lipid transport and exchange, but also in processes such as immune response, inﬂammation and wound
healing. Ongoing proteomics research is focussing on the identiﬁcation of new candidate markers for
cardiovascular disease, the leading cause of death worldwide. The ratio between good cholesterol (high
density lipoprotein) and bad cholesterol (low density lipoprotein) is routinely used to estimate an
individual’s risk for developing premature coronary heart disease. While statin therapy has proven
effects in reducing cardiovascular events, other therapies such as resins, ﬁbrates and niacin have failed to
substantially reduce cardiovascular risk. Thus new targets and candidate biomarkers for risk assessment
and for the development of alternative drugs and treatments of disease are needed. Here we review the
recent ﬁndings in lipoprotein proteomics with the main emphasis on studies that differentially displayed
various states of diseases and on new targeted, high throughput strategies with the capability to translate
discovery ﬁndings into the clinical context of large cohort analyzes.
ã 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Cardiovascular disease (CVD) is the leading cause of death
worldwide [1], and an imbalance between different plasma
lipoprotein classes are a major risk factor for developing this
disease [2]. Lipoproteins form pseudomicellar complexes whichAbbreviations: AGT, angiotensinogen; AHSG, a-2-HS-glycoprotein; ALB, albu-
min; AMBP, bikunin; Apo, apolipoprotein; C3, complement component C3; C4A,
complement component C4A; C4B, complement component C4B; C9, complement
component C9; CETP, cholesteryl ester transfer protein; CFH, H factor 1
(complement); CLEC3A, C-type lectin super family member; CP, ceruloplasmin;
C-RP, C-reactive protein; CSF1, macrophage colony-stimulating factor 1; HLA,
lymphocyte antigen; HPX, hemopexin; HRP, haptoglobin-related protein; ITIH4,
inter-a-trypsin inhibitor heavy chain family 4; KLKB1, plasma kallikrein B1; KNG1,
kininogen-1; LCAT, lecithin-cholesterol acyltransferase; MGEA5, meningioma
expressed antigen 5; N1, notch1; ORM2, orosomucoid 2; oxLDL, oxidized LDL;
PAF-AH, platelet-activating factor acetylhydrolase; PLTP, phospholipid transfer
protein; PON, paraoxonase; RBP4, retinol-binding protein 4; SAA, serum amyloid A;
SAP, serum amyloid P; SERPINA1, a1-antitrypsin; SERPINF1, serpin peptidase
inhibitor, clade F, member 1; SERPINF2, a-2-antiplasmin; SERPING1, complement
component 1 inhibitor; SIGLEC5, sialic acid binding Ig-like lectin 5; TF, transferrin;
TFPI, tissue factor pathway inhibitor; TTR, transthyretin; VTN, vitronectin.
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2212-9634/ã 2015 Published by Elsevier B.V. This is an open access article under the are comprised of a hydrophobic lipid core surrounded by
amphipathic lipids and proteins. Lipoproteins in the blood
transport lipids (triglycerides, cholesterol and phospholipids)
and lipid soluble substances throughout the body. The cholesterol
and phospholipids are used by all cells as building blocks for their
membrane systems. The plasma lipoproteins are classiﬁed
according to their increasing density and decreasing size with
the main classes being very low density lipoprotein (VLDL),
low density lipoprotein (LDL) and high density lipoprotein (HDL).
1.1. The different lipoprotein classes and their physiology
Lipoproteins are synthesized in the liver and small intestine.
VLDL is released by the liver into circulation. The enzymatic action
of lipoprotein lipase (LPL) and hepatic lipase removes triglycerides
from VLDL for storage or energy metabolism. Cholesteryl ester
transfer protein (CETP) further removes triglycerides (and
phospholipids) from VLDL and transfers them to HDL in exchange
for cholesteryl esters [3]. Thus, VLDL is metabolised into the denser
and more cholesterol-rich LDL in the circulation. LDL is taken up by
cells through the LDL receptor pathway [4] and the remaining
VLDL particle is taken up by the LDL-like receptor (VLDLR) [5]. Both
VLDL and LDL deliver triglycerides and cholesterol to the
peripheral tissues for lipid and energy metabolism.CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
A. von Zychlinski, T. Kleffmann / Translational Proteomics 7 (2015) 30–39 31HDL is synthesized in the liver as cholesterol-free, disk-like
particles consisting mainly of apolipoproteins and phospholipids.
In the circulation those complexes accept cholesterol and
phospholipids from cells and other lipoproteins leading to an
increase in HDL particle size. Lecithin-cholesterol acyltransferase
(LCAT) converts the newly assimilated cholesterol into the more
hydrophobic cholesteryl esters which trigger the maturing HDL to
change into its spherical shape. CETP exchanges cholesteryl esters
of HDL against triglycerides of VLDL. Those triglycerides are
degraded by hepatic lipase so that the resulting small HDL particles
are now free to pick up cholesterol again. The action of HDL results
in a net cholesterol ﬂux from the peripheral tissues to the liver
which is known as reverse cholesterol transport. Therefore HDL is
often referred to as the good cholesterol, whereas LDL is
considered the bad cholesterol because it delivers cholesterol to
the periphery of the body. In general high levels of HDL are
favorable and are implicated in a reduced risk of developing CVD,
while high levels of LDL are associated with an increased risk [6].
There are three less often considered lipoprotein classes in
addition to VLDL, LDL and HDL. (i) Chylomicrons are the largest
lipoproteins and transport exogenous lipids to the liver and
peripheral tissues, where LPL removes the triglycerides and the
resulting chylomicron remnants are taken up by the liver. (ii)
Intermediate density lipoprotein (IDL) is a metabolic intermediate
in the maturation from VLDL to LDL when the triglycerides on VLDL
are initially removed by LPL and before its cholesterol content
increases. (iii) Lipoprotein(a) [Lp(a)] is another lipoprotein class
with a still largely unknown function. Elevated plasma Lp(a) levels
are an established, independent and important risk factor for
developing premature CVD and about one ﬁfth of the general
population has elevated plasma Lp(a) levels [7]. Lp(a) is
characterized by its signature protein apolipoprotein(a) [apo(a)],
a high molecular weight glycoprotein. Apo(a) evolved through
gene duplication from plasminogen [8] and consists of multiple
tandem repeats of plasminogen’s kringle 4 domain designated as
KIV type 1 to 10 (KIV-1 to KIV-10) and one kringle 5 (KV) domain.
Unlike plasminogen, apo(a) has an inactive protease domain at the
C-terminus due to a point mutation in the active site. The apo(a)
protein varies in size between individuals due to a polymorphism
in the LPA gene locus resulting in a variable number of KIV-2
repeats [9]. The size of the apo(a) protein ranges between 250 and
900 kDa within the population and is inversely correlated with
plasma Lp(a) levels [10,11].
1.2. Apolipoproteins and lipoprotein-associated proteins
The protein cargo on lipoprotein particles consists of non-
exchangeable and exchangeable apolipoproteins and lipoprotein-
associated proteins. ApoB is considered the only non-exchangeable
apolipoprotein. All other apolipoproteins are thought to be
transferable between different lipoprotein classes. Each lipoprotein
class exhibits a speciﬁc and well characterized core subset of
apolipoproteins [12,13]. VLDL and LDL are often referred to as apoB-
100-containing lipoproteins because they contain one molecule of
apoB-100, a large (550 kDa) structural glycoprotein with many lipid-
binding domains. There is no unique apolipoprotein to distinguish
between VLDL and LDL. However, VLDL is known to carry larger
amounts of apoE and apoCs, whereas LDL contains a lower quantity
of proteins consisting mainly of apo-B100 [14]. Lp(a) is composed of
an LDL-like core particle with apo(a) covalently linked to the apoB-
100 moiety via a single disulphide bond [15]. This gives Lp(a) a
unique apolipoprotein make-up [15–17] with apoB-100 and apo(a)
in an equimolar ratio. HDL, the only non-apoB-containing lipopro-
tein in circulation, is made up of only exchangeable apolipoproteins
[18]. ApoA1 as its major structural protein accounts for around
70–80% of its protein mass by weight and apoA2 for around 20%.Mature HDL particles on average carry 3 apoA1 molecules and a
maximum of 5 apoA1 molecules per particle [19].
The above only describes the core apolipoproteins for each
lipoprotein class. During the last few years proteomics studies have
revealed a more complex picture of apolipoproteins and proteins
associated with different classes of lipoprotein particles [20–29].
Remarkably, all proteomics studies targeting different lipoprotein
classes to date revealed more diverse protein cargos than originally
anticipated [20–29]. Besides the well-established components of
proteins involved in lipid metabolism, these studies discovered
proteins involved in complement system (C4A, C4B, C9, VTN, CLU,
SERPING1, CSF1, HLA, MGEA5, N1, SIGLEC5, CLEC3A, CFH, C3),
inﬂammation (C-RP, CP, C3, HP, SAA, SAP, TTR, TF, PON), protease
inhibition (AGT, SERPINF1/2, AHSG, HRP, SERPINA1, AMBP, KNG1)
and wound healing (FGG, FGA, FGB, HRG) to name only a few. With
the in-depth analyzes of lipoproteins the “classical” apolipoproteins
are now outnumbered by the lipoprotein-associated proteins; e.g.,
the current count for HDL is 71 lipoprotein-associated proteins
versus 18 apolipoproteins (APOA1, APOA2, APOA4, APOA5, APOB,
APOC1, APOC2, APOC3, APOC4, APOD, APOE, APOF, APOH, APOJ,
APOM, APOO, LPA, APOL1). The lipoprotein-associated proteins also
form partof the lipoproteincomplexes, but their presence orabsence
is much more transient. This provoked new hypotheses on more
complex biological functions in which different lipoproteins might
be involved and their impact on the development of CVD.
Furthermore the complex protein proﬁle of lipoproteins includes
lipoprotein-related disease candidate markers that can be evaluated
as diagnostic and/or prognostic tools for CVD.
Traditionally HDL and LDL cholesterol levels – the good and bad
cholesterol – have been and are still used in the clinic to estimate
lipoprotein-associated CVD risk. More recently, the size and
number of lipoprotein particles is seen as a more accurate measure
to determine that risk [30]. Some particles contain less cholesterol
than others. This is especially marked for LDL; particles from
different individuals show a high variability in the amount of
cholesterol they contain [31]. It is noted that the risk of heart
disease is proportional to the number of LDL particles and a
therapeutic aim is to lower the number of LDL particles [31,32]. In
the late 1990s Jim Otvos pioneered and implemented NMR as a
method for measuring lipoprotein particle concentrations [33,34].
This technology became cheaper, making it an increasingly
accessible and more meaningful alternative to asses general
lipoprotein risk factors. Although HDL is seen as the good
cholesterol in epidemiological studies, several recent clinical trials
of therapies increasing HDL levels failed to show improved cardio-
protectivity ([35,36] and summarized on the NHI news webpage
http://www.nih.gov/news/health/may2011/nhlbi-26.htm). A
recent study by Huang et al. showed that a speciﬁc oxidation of
apoA1 leads to dysfunctional HDL that is no longer capable of
transporting cholesterol back to the liver [37]. Therefore unmodi-
ﬁed apoA1 levels in circulation would not serve as a speciﬁc
indicator for atherosclerosis but elevated levels of oxidized apoA1
were associated with an increased CVD risk and may serve as a way
to monitor the progression of disease in the arterial wall [24].
Other modiﬁcations or associated proteins might have similar
detrimental effects on the functionality of the lipoproteins.
Therefore the proteomics characterisation of the protein load of
the lipoprotein classes and their modiﬁcations in the context of
various diseases is of ongoing interest.
2. Are new biomarkers for heart disease hidden within the
protein make-up of lipoproteins?
The great number of single biomarkers which seem to correlate
with cardiovascular risk prediction in the general population does
not necessarily translate well into the prediction of an individual’s
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markers, e.g., inﬂammatory markers show the greatest promise [38].
However, such markers are only effective once a certain disease state
has been established and are therefore generally not suitable for the
prediction of individuals at risk of developing CVD [38]. It is hoped
that lipoprotein-speciﬁc biomarkers may have the power as
prognostic markers to indicate an individual’s susceptibility to
developing disease or to detect the early stages of disease. Two
lipoprotein biomarkers evaluated so far are oxLDL and PAF-AH [39].
Circulating oxLDL as measured by ELISA shows a positive correlation
in patients with advanced atherosclerosis [40], but lacks early
predictive power. PAF-AH remains controversial, given elevated
levels are not convincingly associated with an increased risk of CVD
and that reversible inhibition of the enzyme by “darapladib” did not
reduce major coronary events in clinical trials [39,41].
Apo(a) is an established biomarker for the risk of early
development of CVD [7]. However, it is not yet routinely measured
in the clinic. One reason for this is the lack of a commonly accepted
assay and reference standard [16]. Also there seem to be no
common unit for reporting Lp(a) levels detected by the different
assays (nmol/L, u/L, mg/L), complicating comparison between
results obtained using different methods. The size heterogeneity of
apo(a) adds another variable to be considered in Lp(a) measure-
ments. Furthermore, apo(a) only assesses Lp(a)-related risk and
does not account for other lipoprotein-related risk factors. The
general lack of speciﬁc lipoprotein-related candidate markers was
addressed by various proteomics studies investigating the protein
cargo of different lipoprotein classes. We will brieﬂy review the
early lipoprotein proteomics studies using the more classical two
dimensional gel electrophoresis (2-DE) and shotgun approaches
for global protein proﬁling and will then discuss in more detail
studies that differentially display healthy versus disease states
with special emphasis on targeted quantitative proteomics
strategies such as multiple reaction monitoring (MRM).
So far the good cholesterol – HDL is predominantly targeted by
proteomic studies and has major impact on publications in terms
of numbers and citations (see blue bubbles in Fig. 1). Other
lipoprotein particles have been less considered with Lp(a) being
almost neglected (see Fig. 1).
2.1. Isolation and puriﬁcation of lipoproteins: a ﬁrst step in a successful
proteomics experiment
It is not within the scope of this review to describe in detail the
various isolation and puriﬁcation procedures and evaluate them inFig. 1. Impact of number of publications targeting different lipoprotein particles and ci
number of cumulative citations for the respective publications per particle. Publications
analyzed particles.regard of their suitability for downstream proteomics experi-
ments. The different methodologies have been extensively
reviewed elsewhere [42–44]. However, we must emphasize that
isolation of highly puriﬁed particles should be made a priority
if coherent conclusions are to be made about lipoprotein
class-speciﬁc protein cargos and their functional impact on
lipoprotein biochemistry and pathophysiology.
Density gradient ultracentrifugation is the most widely used
and well established method while immunoprecipitation and
size-exclusion chromatography have been used as alternative or
complementary methods. Density gradient ultracentrifugation
separates the lipoproteins according to their increasing densities in
a salt-gradient and isolates VLDL, LDL and HDL at a suitable purity
when sequential density gradient steps are implemented.
However, density gradient centrifugation is not well suited for
the isolation of Lp(a) because Lp(a) overlaps in density with both
LDL and HDL, hence Lp(a) isolation requires the implementation of
an orthogonal puriﬁcation step [29]. Immunoprecipitation with
anti-apoA1 antibodies is used to isolate apoA1-containing
lipoproteins which are then often referred to as HDL. Although
apoA1 is the main protein component of HDL, it has been described
as a component of VLDL, LDL as well as Lp(a) [20,22,23,26,29,
45–48]. Indeed we showed that Lp(a) can be immunoprecipitated
using an anti-apoA1 antibody [29]. To our knowledge there is no
protein that is unique to just one class of lipoproteins except from
apo(a) on Lp(a) [49]. Each isolation procedure has some draw-
backs. The long running times and high salt concentration during
ultracentrifugation as well as the high ionic strength and extreme
pH during immunoafﬁnity separation might lead to the dissocia-
tion of some lipoprotein-associated proteins. Size exclusion
chromatography is an alternative and more physiological method
but leaves contamination with plasma proteins (summarized in
Chapman and Kontush [50]). At the expense of throughput, we
implemented a 2-dimensional isolation procedure for the major
lipoprotein classes using two sequential orthogonal isolation
procedures i.e., density gradient ultracentrifugation followed by
size exclusion chromatography [48]. This 2-dimensional procedure
isolates Lp(a) at high purity from all other lipoprotein particles. For
the isolation of other lipoprotein classes we hand-selected plasma
samples without a signiﬁcant Lp(a) content to avoid a possible
contamination of Lp(a).
Noting that 20% of the general population have signiﬁcantly
elevated Lp(a) plasma levels, we recommend that LDL and HDL
fractions be regarded as potentially contaminated by co-puriﬁed
Lp(a) unless the samples have been tested for Lp(a). Without such atations per year on lipoprotein research. The width of the bubble is relative to the
 looking at more than one individual particle have been considered for each of the
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treated with caution. With this in mind there is so far no conclusive
evidence of a direct association of apo(a) with any lipoproteins
besides Lp(a). The addition of an average size apo(a) with HDL
would more than double the molecular weight of an HDL particle
[51]. Lp(a) is an independent risk factor for CVD and ideally
individual Lp(a) plasma-levels should be considered and
included in demographic data if conclusions are made about
disease-related markers identiﬁed on different lipoprotein
classes.
2.2. 2-DE maps initial evaluation of the complexity of lipoprotein-
associated protein proﬁles
2-DE provided the ﬁrst snapshots of the LDL [20] and HDL [21]
proteomes in 2005. The LDL study conﬁrmed the presence of
apolipoproteins apoC3, apoE, apoA1, apoM, apoA4, apoJ and apoC2,
which mostly resolved in multiple spots as LDL components. SAA4,
calgranulin A and lysozyme C were further identiﬁed as new
LDL-associated proteins giving a ﬁrst hint of a lipoprotein being
involved in immune and inﬂammatory processes. The description
of the HDL proteome included the ﬁrst attempt to differentially
display speciﬁc lipoprotein subclasses, in this instance HDL2
and HDL3 which represent lower and higher subfractions of HDL
respectively. Salivary alpha-amylase was only displayed on
HDL2 and apoL only on HDL3. The resolved spot pattern suggested
different post-translational modiﬁcations (PTMs) or isoforms
for apoA2 and apoE. The physiological relevance of those PTMs
still remains to be elucidated. In another study displaying the
protein proﬁles of VLDL, LDL and HDL from subjects undergoing
carotid endarterectomy compared to healthy controls, SAA was
found to be up-regulated in all three lipoprotein classes [52].
In a study comparing LDL from obese and normal weight subjects,
TTR, clusterin (apoJ), apoC2, a1-antitrypsin and an acidic isoform
of apoA1 were upregulated, whereas the main apoA1 isoform and
apoA4 were down-regulated [22]. In addition a male speciﬁc
down-regulation of apoE and up-regulation of non-sialylated
apoC3 was reported. Using ﬂuorescence difference gel
electrophoresis (DIGE) to compare HDL2 and HDL3 with healthy
controls in acute coronary syndrome [53] revealed apoA1,
apoA4, apoE and apoL1 to be up-regulated on HDL3,
whereas those proteins are down-regulated in HDL2 in the
disease subjects (for details on other regulated proteins see
Table 1).
Two-DE allows for semi-quantitative comparison of relative
protein abundances between two or more samples. However, for
LDL [20] and later VLDL [23] the size and poor solubility of their
major protein component apoB-100 does not allow for this protein
to be displayed on 2-DE, making conclusions about the actual
protein cargo and abundances difﬁcult. The apparent difﬁculties in
displaying the protein complements of lipoproteins, especially
those of apoB-100 containing lipoproteins, makes 2-DE a laborious
and less accurate method for quantiﬁcation of this set of proteins.
Furthermore, to gain comprehensive and conclusive information
about relative protein abundances and PTMs from 2-DE gels,
ideally all spots had to be analyzed. This labor and time intense
procedure has successfully been used to perform whole pathway
analyzes and model developmental processes [54,55] in cellular
systems. This approach is difﬁcult for lipoproteins since so far
protein identiﬁcations from 2-DE gels comprise only a small
number of proteins per lipoprotein class, 11 for VLDL and LDL and
13 for HDL [20,21,23]. All classes of lipoproteins are comprised
(at least partially) of lipophilic proteins and proteins covering a
great range of abundance of size [from very small (<10 kDa) to very
large proteins (>300 kDa)] and of isoelectric point, including
proteins outside the displayed pH range (e.g., apoC1 is one of themost positively charged proteins in plasma). Those proteins fail to
be displayed by 2-DE which explains why only a very small number
of proteins were identiﬁed per lipoprotein class.
2.3. Shotgun proteomics discovered a complex array of proteins
associated with lipoprotein particles
Shotgun proteomics approaches have a greater potential to
cover the entire proteome of lipoproteins. The ﬁrst HDL data-set
was published in 2006 [24]. This study used 1-DE, 2-DE and
shotgun-MS to analyze the HDL proteome. The authors used a
clever approach to eliminate high abundance apoA1 peptides, the
major protein component of HDL by analysing only cysteine
containing peptides using the isotope-coded afﬁnity tag (ICAT)
labeling strategy, exploiting the fact that apoA1 does not contain
cysteine residues. This approach improved the chance to identify
lower abundant proteins on HDL and thus for the ﬁrst time
identiﬁed as HDL-associated proteins, inﬂammatory markers
(C-RP, CP, C3, HP, SAA, SAP, TTR, TF, PON), immune system and
complement factors (SERPING1, CSF1, HLA, MGEA5, N1, SIGLEC5,
CLEC3A, CFH, C3), and proteins involved in hemostasis and
thrombosis (KLKB1, TFPI). This more complex protein cargo of
HDL was later conﬁrmed and further extended by additional
proteins of the complement system (C4A, C4B, C9, VTN, CLU) and
proteins playing a role in protease inhibition (AGT, SERPINF1/2,
AHSG, HRP, SERPINA1, AMBP, KNG1) and acute-phase response
(ORM2, ITIH4, RBP4, HPX) [25]. Other studies followed, mainly
targeting HDL using a variety of techniques making the HDL
proteome the best annotated proteome of all lipoprotein classes
(see Fig. 1) [26–28]. The current state of the HDL proteome can be
viewed on the HDL Proteome Watch (http://homepages.uc.edu/
~davidswm/HDLproteome.html) which aims to track, cite and
combine all HDL proteomics publications into an updated list of
HDL-associated proteins.
The characterization of the LDL and VLDL proteomes is lagging
behind. Sun et al. [46] monitored the physiological transition from
VLDL to LDL using an Isobaric tags for relative and absolute
quantiﬁcation (iTRAQ) approach in combination with 2-DE.
ApoB-100 represented the static component during this process,
whereas all other proteins could be exchanged. The relative
abundance of all apoCs together with apoE, SAA4 and apo(a)
declined from VLDL to LDL, whereas PON1, apoM, apoF and ALB
accumulated and apoA1, apoA2 and apoL-1 remained constant. The
results were conﬁrmed by western blots using antibodies against
all of the above proteins except apo(a). The apoCs and apoE are
known regulators and mediators in triglyceride and cholesterol
metabolism [56] and a change in their abundances underpins their
importance in the transition from VLDL to LDL. Including IDL as a
metabolic intermediate in further studies would help to extend
this view. The balance between the identiﬁed proteins might be an
important indicator for a favorable versus unfavorable lipid proﬁle.
More recently Dashty et al. made further attempts to compare the
whole protein cargos of VLDL and LDL by shotgun-proteomics [45]
generating a large catalog of LDL and VLDL-associated proteins (56
and 95 identiﬁcations respectively) which they clustered into three
disease-related categories (dyslipidaemia, atherosclerosis and
vascular disease and coagulation disorders). However, the large
number of single peptide-based protein identiﬁcations and the
detection of proteins such as apo(a), hemoglobin, GAPDH and
others suggests the need for further conﬁrmative experiments
including additional quality controls for particle purity and careful
validation of protein identiﬁcations.
The increasing sensitivity of analytical procedures in shotgun
proteomics led to the identiﬁcation of an increasing complexity of
lipoprotein-associated proteins with a variety of different and
novel functions assigned to lipoproteins. However, as in all
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evaluation of true positive protein identiﬁcations is required to
generate a reliable and conﬁrmed catalog of particle-associated
proteins suitable for further research on candidate biomarkers.
Furthermore, more accurate quantitative information of each
protein on different particles is crucial for the ongoing search of
candidate biomarkers.Table 1
List of studies that differentially quantiﬁed lipoprotein-associated proteins between dis
disease cohorts.
Ref. Cohort Lp Method Differences versus cont
[90] CAD HDL Normalized spectral
count using ScaffoldTM
78 proteins show subst
[91] Acute coronary
syndrome
HDL Normalized spectral
count using ScaffoldTM
and emPAI
Shift to inﬂammatory p
subunit#, apoAIV#, gels
PGRP2#, SAA", HRP", ﬁb
C3")
[92] Uremia HDL Peptide index based on
peptide abundance
SP-B", apoCII, SAA", AM
[93] Psoriasis HDL Peptide count 17 additional proteins i
apoM#, SAA", prothrom
glycoprotein1", apoAII"
[94] Uremia HDL Spectral count Albumin", SAA1", apoC
RBP4", transthyretin", L
[25] CAD HDL Spectral count apoCIV", PON1", compl
[95] Insulin resistance,
obesity,
dyslipoproteinemia
HDL AQUA apoJ# 
[96] CAD HDL2 MALDI-TOF signatures,
PLS-DA (partial least
squares discriminant
analysis)
Oxidized methionine o
apoCI"
[97] Endotoxemia HDL SELDI-TOF MS Changes in 21 markers
PON1"
[67] CAD HDL3 Spectral count
conﬁrmed with
extracted ion
chromatograms
apoE#, apoF", PLTP", ap
[53] ACS HDL2
& 3
DIGE HDL3: apoA1", apoAIV"
a1B-glycoprotein", SAP
FGG", Rab-7b#
HDL2: apoA1#, apoE#, P
haptoglobin#, hemopex
complement factor B#, 
C#, SAP", alpha-1-anti t
vitamin D binding prot
[22] Obesity LDL 2-DE TTR", apoJ", apoC2", a1
isoform apoA1", apoAIV
apoE#, non-sialylated a
[52] Carotid
atherosclerosis
VLDL,
LDL,
HDL
2-DE SAA" 
[98] Percutaneous
transluminal
coronary
angioplasty
HDL Stable isotope labeling
(iTRAQ, 18O)
High inter-individual va
Ref: reference; cohort: analyzed disease cohorts; Lp: analyzed lipoproteins; method: me
down-regulated in disease cohort.2.4. Label-free shotgun proteomics as a tool for global quantitative
proteomics
Label-free shotgun approaches, when designed appropriately,
also provide semi-quantitative information of relative and abso-
lute protein abundances. The different strategies and software
tools for label-free quantiﬁcation of proteins from large-scale
bottom-up approaches have been extensively reviewed elsewhereease and control cohorts and the main ﬁndings of altered protein abundance in the
rols Notes
antial differences
roﬁle (hemoglobin beta
olin#, carbonic anhydraseI#,
ronectin", complement
BP", PEDE", transferrin"
n disease plus apoAI#,
bin", a1-acid
, a1-antitrypsin", IgA-1"
III", antitrypsin", apoAVI",
p-PLA2"
ement C3", apoAIV", apoE"
Further showed that apoJ on VLDL/LDL levels are
inversely to the levels on HDL
n apoA1, apoCIII", Lp(a)", The discovery of Lp(a) as a potential marker in CVD
patients is not surprising. Lp(a) is a major risk factor
for developing CVD. Although this ﬁnding might be
of biological relevance, it does not make Lp(a) a
biomarker for HDL related CVD risk but rather
indicates contamination of HDL2 with Lp(a)
, discussed only SAA1/2",
oJ"
, apoE", apoL1", PON1",
", vitamin binding protein",
ON1#, apoAIV#, apoL1#,
in#, serotransferrin#,
Rab-7b#, FGG#, IgG-1 chain
rypsin", acid ceramidase",
ein"
-antitrypsin", acidic
#, main apoA1#, plus men:
poC3"
Only 8 unique proteins were identiﬁed
riability Identiﬁcation of 111 new HDL-associated proteins
(225 in total). Study has not been included in the
HDL proteome watch list
thod used for relative or absolute quantiﬁcation; " up-regulated in disease cohort; #
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used for quantitative proteomics of lipoproteins. Spectral counting
is probably the most extensively used method for protein
abundance estimation from shotgun proteomics data sets. The
number of fragment ion spectra acquired for all signiﬁcantly
identiﬁed peptides assigned to a speciﬁc protein or protein group
correlates with the abundance of the respective protein [60,61].
This raw number of spectral counts can be used for relative
quantiﬁcation of proteins between two or more samples if the
sample complexity and composition is very similar. For more
reliable and accurate quantiﬁcation, normalization procedures for
spectral counts have been implemented to account for run to run
variations such as differences in LC–MS method-dependent
sampling of precursor ions for data-dependent MS/MS acquisition
or the expected contribution of spectra per protein in relation to
the length of a protein [62,63]. Similar to normalized spectral
counting, methods based on the number of experimentally
observed peptide counts normalized to the number of theoretically
expected peptides per protein such as emPAI (exponentially
modiﬁed protein abundance index) have been developed for
relative and absolute quantiﬁcation [64,65]. As an alternative
to these approaches which quantify on the MS/MS level, intensity-
based quantiﬁcation of MS signal intensities are used for relative
and absolute quantiﬁcation. The Top3 approach which uses the
area under the curve of the three strongest peptide signals per
protein for relative and absolute quantiﬁcation is easy to
implement as it does not require the alignment of ion chromato-
grams [66].
In shotgun proteomics of lipoproteins spectral counting
(sometimes misleadingly referred to as peptide counts) has been
frequently used because the number of spectra can easily be
extracted from database search results. Vaiser et al. [25] and
Davidson et al. [27] for instance estimated the relative amount of
proteins detected on puriﬁed particles from HDL subclasses.
Davidson et al. [27] used spectral counts to further break the HDL
proteome down into clusters of proteins prevalently associated
with distinct subpopulations of HDL isolated from normolipidemic
individuals. They could show that the abundance of proteins
enriched on the low density HDL3 subclass such as apoL1, PON1/2
and PON3 correlates with the protection of LDL oxidation by HDL3
and that other proteins such as apoD, SAA4, apoM, apoJ and PLTP
are enriched on the subpopulation of HDL3 with antioxidant
activity. This combination of proteins could serve as a panel of
targets to be evaluated as markers for the antioxidant capability of
HDL in the context of CVD [27]. Vaiser et al. [25] quantitatively
compared the protein complement of HDL3 isolated from 6 healthy
men versus 7 men with established coronary artery disease (CAD).
They identiﬁed a signiﬁcant enrichment of apoC4, PON1, comple-
ment component C3, apoA4 and apoE on HDL3 from CAD patients
compared to healthy controls. The elevated apoE-levels on HDL3
from CAD patients was further conﬁrmed by an orthogonal
immunological method in a different cohort of 32 healthy versus
32 subjects with established CAD, supporting the potential
signiﬁcance of apoE as a candidate marker for CAD [25]. A
follow-up study by the same laboratories [67] investigated the
protein proﬁle of HDL3 in 6CAD subjects before and one year after a
combined statin and niacin therapy using spectral counts and
precursor ion peak intensities of high resolution FT-MS ion
chromatograms for relative quantiﬁcation. This quantitative
approach showed that apoE levels on HDL3 were lowered in
CAD subjects upon statin and niacin treatment while the
abundance of apoF, PLTP and also apoJ (clusterin) increased.
Such studies demonstrated that quantitative discovery proteo-
mics using spectral counting as well as precursor peak intensities
provide sufﬁcient quantitative information of proteins associated
with lipoproteins to investigate differences between CVD andhealthy subjects or elucidate the differential protein cargo on HDL
subpopulations. However, Davidson et al. [27] also point out that
spectral counting as performed in these studies only allows for
relative quantiﬁcation of the same protein in different samples and
that the method might be less accurate for certain proteins such as
very small proteins represented by a low number of peptides with
poor MS signal response. In fact the here discussed methods for
label-free quantiﬁcation have been evaluated in the context of very
complex proteomes such as whole cell lysates and serum
[65,68,69] whereas the small subset of proteins associated with
lipoprotein particles is highly variable in terms of physico-
chemical properties and sizes. There are highly glycosylated
>300 kDa proteins (apoB-100) with highly repetitive sequence
domains (apo(a) kringle domains) as well as very small (apoC1/C2/
C3 and apoA2 are all smaller than 9 kDa), very hydrophobic
(apoB-100, which is only soluble in its lipid context) and very
positively charged (apoC1) proteins in a subset of only approxi-
mately 30–50 protein species. We have compared the abundance
measurement of emPAI and Top3 performed on a shotgun analysis
of pooled VLDL samples spiked with proteotypic stable isotope
labeled standard (SIS) peptides for absolute quantiﬁcation (AQUA)
of 12 lipoprotein-associated proteins. The absolute protein
abundance normalized to apoB-100 measured by the emPAI
method correlated poorly with the AQUA method (R2 = 0.552) and
overestimated the abundance of the large apoB-100 protein
compared to the high numbers of small apoC proteins on VLDL.
The Top3 method showed a better but still low correlation
(R2 = 0.901) indicating the limitations of label-free methods for the
accurate quantiﬁcation of the distinct protein subset associated
with lipoproteins (data not shown).
2.5. Absolute quantiﬁcation of lipoprotein-associated proteins
We have recently conducted an AQUA approach on 17 proteins
associated with total HDL, VLDL, LDL and Lp(a) using proteotypic
SIS peptides to elucidate the average stoichiometry of apolipo-
proteins and associated proteins on the different particle classes
[48]. For apo-B100 containing lipoprotein particles the measured
amount of apoB-100 molecules directly correlates to the number of
particles because every LDL, VLDL and Lp(a) particle contains
exactly one molecule of apoB-100 so that the average number of
every targeted protein species per particle can be calculated. This
approach showed strong quantitative differences in the protein
cargo between the particle classes isolated from the same
individuals as well as large variations in the number of certain
apolipoproteins on the same particle class isolated from different
individuals. Strong differences were seen in the distribution of
apoC1, apoC2 and apoC3 throughout all lipoprotein classes with
the highest average numbers of 48 and 37 molecules per VLDL
particle measured for apoC2 and apoC3 respectively. In contrast to
these high numbers of apoC molecules we measured only low
numbers for non-apolipoproteins such as complement compo-
nents C3 and C4-A, PON1, PAF-HA and also clusterin (apoJ) on all
analyzed particle classes. On HDL for example the ratios between
apoA1 and C4-A, clusterin and PON1 were 0.003, 0.001 and 0.078
respectively indicating that roughly every 100th HDL particle may
carry one molecule of C4-A (considering an average of three apoA1
molecules per HDL particle). The stoichiometry of proteins
associated with lipoprotein particles would be expected to have
a great impact on the function of the respective particle class.
Pathway enrichment analyzes of shotgun proteomics data from Lp
(a) particles has indicated a signiﬁcant contribution to the
biological process of “response to wound healing” with a more
signiﬁcant enrichment score than lipid metabolic processes [29].
However, absolute quantiﬁcation of Lp(a)-associated proteins
revealed that the number of protein molecules involved in
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of protein molecules per particle [48] (Fig. 2). Although these
results suggest that response to wound healing may not be the
main physiological function of Lp(a), quantitative variations of this
particular protein load could have a strong impact on atherogenic
and thrombotic properties of Lp(a) [29]. The knowledge of the
stoichiometry of lipoprotein-associated proteins on different
particle classes provides important insights into the physiology
of lipoproteins and the calculated amounts between various
apolipoproteins and apoB-100, apo(a) or apoA1 can improve the
interpretation of quantitative measurements of apolipoproteins
directly in plasma using high throughput targeted approaches.
2.6. Targeted proteomics as a tool to translate discovery data into large
cohort analyzes
In recent years mass spectrometry-based targeted proteomics
gained increasing attention and new targeted strategies for high
sensitivity monitoring of proteins in complex matrices have been
developed. Driven by the need for more sensitive and quantita-
tively more reliable methods, MRM also referred to as selected
reaction monitoring (SRM), which is traditionally and most
frequently used in pharmaceutical research and analytical
chemistry, has been adapted and reﬁned for the use in targeted
proteomics. Triple quadrupole mass spectrometry is the work-
horse of MRM-based targeted proteomics with the ﬁrst quadrupole
functioning as a mass selective ﬁlter to eliminate sample
complexity. Radio frequency and direct current amplitude settings
applied to the quadrupole are precisely calibrated to allow a stable
trajectory through the dynamic electric ﬁeld for only those ions
with an m/z of the selected precursor. The precursor of interest
then enters the second quadrupole which functions as a collision
cell to generate fragment ions. The third quadrupole is again used
as a mass selective ﬁlter to pass only one fragment ion species
through to be monitored at the detector. The fragment ions are
referred to as transitions and usually 2 or 3 transitions are
monitored per precursor to increase speciﬁcity. For every
transition the instrument cycles through the described sequence
of quadrupole settings. The chromatographic retention time is
used as an additional bit of information to further increase
speciﬁcity of detection. The intensity proﬁle of one or more
transitions monitored at the detector over time is used for relative
quantiﬁcation or absolute quantiﬁcation if internal standards are
included. Thus the establishment of MRM assays requires the prior
knowledge of precursor m/z, fragmentation pattern (m/z ofFig. 2. Adjustment of shotgun proteomics data of Lp(a) [29] with the actual number of p
functional pathway analysis of the Lp(a) shotgun data assigns the majority of protein 
correlation p-value for overrepresented pathways than “lipid metabolic processes” (gre
AQUA reveals that only a small proportion of 5% of the total number of proteins molecu
molecules per particle are involved in “lipid metabolic processes”.strongest transitions) and chromatographic retention time. When
all these parameters are optimized, MRM shows a robust and
accurate quantiﬁcation over a large number of samples and even
between different laboratories and is therefore an adequate
method for the detection and quantiﬁcation of candidate
biomarkers in large clinical cohorts [70].
MRM has been successfully applied to the detection and
quantiﬁcation of HDL-associated proteins on puriﬁed particles
[71,72] and on apolipoproteins directly in plasma [73–82]. The
MRM assays showed low intra- and interassay variation as well as
good correlation with orthogonal methods such as immunoassays
[71,72,74,76]. Yassine et al. [72] compared the quantiﬁcation of a
panel of HDL-associated proteins on puriﬁed particles from poole
d plasmasamplestaken fromtennormalversustenCVDsubjectsbya
highly sensitive multiplexed immunoassay versus MRM assays.
The immunological method was still superior for the detection and
quantiﬁcation of very low abundant proteins and quantiﬁed
69 proteins. Using MRM 32 proteins could be detected and 11 of
them showed a coefﬁcient of variation (CV) below 20% in four
consecutive measurements. Although the immunoassay had a
higher sensitivity, the quantiﬁcation between both methods
correlated positively for most of the proteins. Only the quantiﬁcation
of apoD, apoC3 and apo(a) did not correlate well between the
different methods. Yassine et al. [72] discuss that highly
homologous proteins such as the members of the alpha-2 micro-
globulin protein superfamily might interfere with the immunologi-
cal detection of apoD, a member of this protein superfamily.
They also point out that proteotypic peptides used as internal
standards for the MRM assays might not differentiate between
various protein isoforms such as multiple isoforms of apoC3. As
aforementioned the detection of apo(a) on HDL is debatable and
the demographic data does not include Lp(a) levels of blood donors
to estimate a potential Lp(a)-reated risk. Nevertheless, Yassine
et al. [72] found apoC1, apoC2 and PON-1 reduced in the CVD
sample whereas acute phase proteins were enriched on HDL from
CVD patients. Interestingly Rezeli et al. [78] found elevated levels
of apoC1, apoC2 and apoE in patients with ST-segment elevated
myocardial infarction (STEMI) versus patients with chest pain
when measuring a panel of 11 apolipoproteins by MRM directly in
plasma. Both studies quantiﬁed apolipoproteins in a different
context of CVD (markers for lipoprotein-related CVD versus acute
myocardial infarction) and demonstrated the use of MRM assays to
accurately quantify potential lipoprotein-related markers either as
risk indicators or acute disease markers. However, MRM assays
have a lower sensitivity compared to immunoassays [72] androtein molecules per particle analyzed by absolute quantiﬁcation (AQUA) [48]. (A)
species to “response to wounding” (red circled area of the network) with a better
en circled area) [29]. (B) The average number of proteins per particle measured by
les contributes to “response to wounding” whereas the majority of 95% of protein
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of high abundance proteins, when low abundance proteins are
targeted [73,74,78].
Immunoafﬁnity capture of target molecules coupled to mass
spectrometric detection and quantiﬁcation has been developed to
improve sensitivity and speciﬁcity compared to basic MRM assays.
Target molecules can either be captured and measured as intact
proteins which includes the detection of all protein variants and
modiﬁcations above a certain threshold (discussed in Yassine et al.
[43]) or as proteotypic peptides in a bottom-up approach such as
Stable Isotope Standards and Capture by Anti-Peptide Antibodies
(SISCAPA) [83]. In a SISCAPA approach the digested protein sample
is spiked with a SIS peptide corresponding to the target peptide
which is then captured together with the endogenous peptide by
immunoafﬁnity puriﬁcation on immobilized anti-peptide anti-
bodies. SISCAPA workﬂows have been further developed by
coupling solid-phase extraction procedures inline to MRM
analyzes (instead of reverse phase chromatography) to drastically
reduce cycle time and increase sample throughput [84] which
enables the usage of immunoafﬁnity capture MRM assays in a large
scale clinical context for biomarker validation. To our knowledge
they have hitherto not been used for lipoprotein-related markers in
the context of CVD. Research on lipoprotein-related candidate
biomarkers for CVD however, is still in transition between
discovery and evaluation phase and MRM assays and especially
SISCAPA approaches lack ﬂexibility in method development. New
target proteins, which become relevant, based on novel ﬁndings
and reﬁned hypotheses, cannot easily be added to the existing
method. This is also a general disadvantage of MRM assays because
no data will be recorded for any other molecule but those targeted
for acquisition. For the inclusion of novel targets the MRM assays
must be repeated, ideally including previous targets for a direct
comparison. Furthermore, MRM assays with great numbers of
compounds require laborious and challenging method develop-
ment to optimize LC conditions, select MRM transitions and
accurately schedule the acquisition of a large number of
compounds throughout the chromatographic elution proﬁle.
2.7. New strategies for global and targeted protein quantiﬁcation
Hyper-reaction monitoring-MSTM (HRM-MSTM) is a new concept
of global protein quantiﬁcation using data-independent acquisition
(DIA)to circumvent someof the limitations ofMRMassays (reviewed
in Law and Lim [85]). DIA records all transitions of all precursor ions
above the detection limit of the mass spectrometer throughout the
chromatographic elution by high resolution mass analyzers such as
Q-Exactive (Q-Orbitrap) and TripleTOF(QqTOF) mass spectrometers.
SWATH-MS is one DIA strategy using the concept of HRM for global
protein quantiﬁcation [86,87]. In a SWATH-MS experiment, typically
performed on a TripleTOF mass spectrometer, the instrument cycles
through consecutive 25 m/z precursor isolation windows
(or variable windows in the latest instruments) and records all
fragment ions of each isolation window in a combined fragment
spectrum. Over the typical mass range of m/z 400–1250 thirty two
complex fragment spectra are acquired during a cycle time of 3.3 s.
Such complicated MS/MS spectra cannot be analyzed by conven-
tional software tools for database-dependent protein identiﬁcation.
SWATH-MS data interpretation depends on spectral libraries which
have to be either acquired by shotgun approaches using
data dependent acquisition (DDA) or compiled from available data.
Retention time alignment between the DDA and DIA datasets, is a
crucial requirement for the correct assignment of SWATH-MS
fragment ion data [87]. However, SWATH-MS and other strategies
for data-independent acquisition combine discovery capabilities
and MRM-like quantiﬁcation with targeted hypothesis-driven data
analysis and provide a powerful tool for ﬁnding new targets forlipoprotein related biomarker candidates. To our knowledge, thus
far there is no study investigating the relative and absolute
abundance of lipoprotein-associated proteins in the context of
CVD using DIA-MS approaches.
2.8. Critical remarks on lipoprotein proteomics studies
For lipoprotein proteomics studies in general there is a need to
establish international standardization procedures. Unfortunately
even the basic minimum information about a proteomics
experiment (MIAPE) guidelines [88] are not always documented
in the publications and might not even be implemented to their full
extend. We would like to emphasize their full implementation for
future lipoprotein proteomic studies. Moreover, we would like to
recommend the implementations of established standard operat-
ing procedures (SOPs) for serum and plasma collection to minimize
the variability for downstream proteomics analysis. Such SOPs
have been established by the Early Detection Research Network
(EDRN) [89] and are publicly available (http://edrn.nci.nih.gov/
resources/standard-operating-procedures/standard-operating-
procedures). Unfortunately, it is commonly not mentioned for any
of the lipoprotein proteomic studies, if the plasma/serum was
collected following the appropriate SOPs.
For other research, especially for cancer proteomics, interna-
tional consortia are aware of the need for method validation and
reproducibility. Therefore, the Clinical Proteomic Tumor Analysis
Consortium (CPTAC) was established with the aim to ensure
inter-laboratory data reproducibility in cancer samples. Similar
efforts should be undertaken for lipoprotein proteomics studies.
3. Conclusion
CVD remains the leading cause of death worldwide indicating the
need for suitable predictive disease biomarkers. However, the
complexity of CVD events makes any single marker unreliable and
most currently applied markers fail to predict early preclinical risk.
Lipoprotein-related biomarkers potentially hold the promise to ﬁll
this gap. A number of studies have attempted to unravel speciﬁc
candidate markers by looking at a variety of different cohorts.
However, the search for new lipoprotein-associated biomarkers is
still in the discovery or early evaluation state and larger cohort
analyzes are needed. New advanced MS-based approaches such as
MRM and HRM-MSTM have a great potential to identify and quantify
hundreds of candidate marker proteins in one sample and allow the
translation from isolated lipoproteins to whole plasma. Novel DIA
approaches are exciting strategies to proteome quantiﬁcation that
provides an individual multiplexed proteomic ﬁngerprint. Such
approaches in conjunction with HRM have the potential to become
the gold standard for future targeted proteomics on lipoproteins in a
discovery as well as more clinical research context.
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